Key facts
- It has raised $4.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Cowin Capital, Goldport Capital, ASB Ventures, China Venture Capital, Feixi County Industrial Park Investment Holding (Group).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Oryza Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Oryza Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oryza Pharmaceuticals
Developer of innovative drugs designed to provide better treatment for patients. The company offers research and development of innovative drugs for diabetes, digestive system diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and the pharmaceutical preparations process, thereby providing advanced treatment solutions for medical industrial users.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2016
- Employees
- 14
- Website
- oryzapharma.com.cn/
- Ownership
- Privately Held (backing)
Oryza Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oryza Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oryza Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.